BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 6253098)

  • 1. Clinical experience with misonidazole: high dose fractions versus daily low doses.
    Kogelnik HD
    Cancer Clin Trials; 1980; 3(2):179-86. PubMed ID: 6253098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical experience with daily doses of misonidazole (author's transl)].
    Kogelnik HD; Reinartz G; Szepesi T; Seitz W; Wurst F; Mamoli B; Wessely P; Stark H
    Strahlentherapie; 1980 Nov; 156(11):758-64. PubMed ID: 7434385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Further clinical experiences of a phase I study with the hypoxic cell radiosensitizer misonidazole.
    Kogelnik HD; Meyer JH; Jentzsch K; Szepesi T; Kärcher KH; Maida E; Mamoli B; Wessely P; Zaunbauer F
    Br J Cancer Suppl; 1978 Jun; 3():281-5. PubMed ID: 209810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Misonidazole in the preoperative and radical radiotherapy of bladder cancer.
    Awwad HK; El Merzabani MM; El Badawy S; Ezzat S; Akoush H; Abd El Moneim H; Saiid A; Soliman O; Khafagy M; Burgers MV
    Cancer Clin Trials; 1980; 3(3):275-80. PubMed ID: 7438324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Misonidazole in the clinic at Mount Vernon.
    Dische S
    Cancer Clin Trials; 1980; 3(2):175-8. PubMed ID: 7000388
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials.
    Dische S; Saunders MI; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():318-21. PubMed ID: 209811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of hypoxic cell sensitizer (Misonidazole)].
    Asakawa H; Watarai J; Hoshino T
    Gan To Kagaku Ryoho; 1984 Jun; 11(6):1225-30. PubMed ID: 6732250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Final report on the United States Phase I Clinical Trial of the hypoxic cell radiosensitizer, misonidazole (Ro-07-0582; NSC #261037).
    Phillips TL; Wasserman TH; Johnson RJ; Levin VA; VanRaalte G
    Cancer; 1981 Oct; 48(8):1697-704. PubMed ID: 6269723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Misonidazole peripheral neuropathy: its relationship to plasma concentration and other drugs.
    Walker MD; Strike TA
    Cancer Clin Trials; 1980; 3(2):105-9. PubMed ID: 6253094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New side effect of the hypoxic cell sensitizer, misonidazole.
    Partington J; Koziol D; Chapman D; Rabin H; Urtasun RC
    Cancer Treat Rep; 1979 Jan; 63(1):123-5. PubMed ID: 217536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical experiences with the radiation-sensitizing agent misonidazole].
    Kogelnik HD; Szepesi T; Kärcher KH; Seitz W
    Strahlentherapie Sonderb; 1978; 75():115-9. PubMed ID: 162327
    [No Abstract]   [Full Text] [Related]  

  • 12. Plasma concentrations of misonidazole.
    Notter G; Rylander U; Turesson I
    Strahlentherapie; 1980; 156(10):714-8. PubMed ID: 7434379
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum.
    Saunders ME; Dische S; Anderson P; Flockhart IR
    Br J Cancer Suppl; 1978 Jun; 3():268-70. PubMed ID: 209808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Misonidazole in fractionated radiotherapy: are many small fractions best?
    Denekamp J; McNally NJ; Fowler JF; Joiner MC
    Br J Radiol; 1980 Oct; 53(634):981-90. PubMed ID: 7426922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peripheral neuropathy related to misonidazole: incidence and pathology.
    Urtasun RC; Chapman JD; Feldstein ML; Band RP; Rabin HR; Wilson AF; Marynowski B; Starreveld E; Shnitka T
    Br J Cancer Suppl; 1978 Jun; 3():271-5. PubMed ID: 209809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Postoperative radiotherapy of astrocytomas grade 3 and 4 with the radiosensitizer misonidazole. -End results of a multicentric controlled German study].
    Sack H; Calcanis A; Godehardt E; Weidtman V; Zülch KJ; Ammon J; Bamberg M; Herbst M; Keim H; Kleibel F; Makoski HB; Potthoff PC; Schlegel G; Schnepper E
    Strahlentherapie; 1982 Aug; 158(8):466-9. PubMed ID: 6753245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical trials of hypoxic cell sensitizer misonidazole].
    Onoyama Y
    Gan No Rinsho; 1983 May; 29(6):718-25. PubMed ID: 6348345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole.
    Coleman CN; Friedman MK; Jacobs C; Halsey J; Ignoffo R; Leibel S; Hirst VK; Gribble M; Carter SK; Phillips TL
    Cancer Res; 1983 Oct; 43(10):5022-5. PubMed ID: 6883348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Misonidazole-a drug for trial in radiotherapy and oncology.
    Dische S; Saunders MI; Flockhart IR; Lee ME; Anderson P
    Int J Radiat Oncol Biol Phys; 1979 Jun; 5(6):851-60. PubMed ID: 227822
    [No Abstract]   [Full Text] [Related]  

  • 20. The effects of misonidazole during continuous low dose rate irradiation.
    Fu KK; Hurst S; Begg AC; Brown JM
    Cancer Clin Trials; 1980; 3(3):257-65. PubMed ID: 7438323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.